

Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study

NCT05089227

| | |
|-------------------|--|
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Enrollment | 72 participants |

Key Eligibility Criteria

Inclusion (8)

- Patient aged e 18 years
- Patient with a diagnosis of primary or secondary autoimmune hemolytic anemia (AIHA) (infections, hematologic diseases, systemic diseases), according to the following criteria:
- Hemoglobin ≤ 12 g/dL
- and decreased haptoglobin (≤ 0.4 g/L)
- and positive direct antiglobulin test (direct Coombs test) (IgG +/- C3d)
- ... and 3 more (see full listing online)

Exclusion (29)

- Patients with immediate symptomatic VTE, confirmed by appropriate complementary examinations (venous Doppler of the lower limbs, thoracic angioscanner or pulmonary scintigraphy).
- Patients on curative anticoagulation (venous thromboembolic disease, atrial fibrillation)
- Patient on dual antiaggregation treatment
- Patient with active bleeding
- Patient with a known condition or lesion at risk of bleeding
- ... and 24 more (see full listing online)

Locations (1 total)

Chu Dijon Bourgogne, Dijon, France